📊 GMED Key Takeaways
Is Globus Medical Inc. (GMED) a Good Investment?
Globus Medical demonstrates strong operational fundamentals with 16.7% revenue growth, exceptional free cash flow generation ($588.8M, 20% FCF margin), and a pristine balance sheet with no debt. The company is efficiently converting cash to shareholder value, evidenced by 422.7% EPS growth despite flat net income, indicating disciplined capital allocation through buybacks.
Globus Medical shows solid double-digit revenue growth, strong free cash flow generation, and a debt-free, highly liquid balance sheet, indicating resilient fundamentals and capacity to invest. Despite flat net income year over year and mid-teens operating margins, cash conversion is robust and supports potential margin expansion with scale and mix improvements. On fundamentals alone, the profile is attractive if gross margin and operating leverage trend upward.
Why Buy Globus Medical Inc. Stock? GMED Key Strengths
- Outstanding free cash flow generation at 20% of revenue with minimal capex burden
- Fortress balance sheet: zero debt, $526.2M cash position, 4.26x current ratio for substantial financial flexibility
- Solid revenue growth of 16.7% YoY in defensive healthcare sector with healthy profitability margins (18.3% net, 16.3% operating)
- Strong capital allocation strategy evidenced by EPS growth acceleration (+422.7%) through share buybacks despite flat net income
- High return on assets (10.1%) and equity (11.8%) demonstrate efficient capital deployment
- Debt-free balance sheet with strong liquidity (current ratio 4.26x, cash ~$526M)
- Robust cash generation (OCF > NI, ~20% FCF margin)
- Healthy profitability and returns without leverage (OM 16.3%, ROE 11.8%)
GMED Stock Risks: Globus Medical Inc. Investment Risks
- Net income grew 0% YoY despite 16.7% revenue growth, suggesting either margin compression or non-recurring items that warrant investigation
- Medical device sector faces regulatory headwinds, competitive pricing pressure, and dependency on discretionary surgical procedures
- Elevated insider trading activity (17 Form 4 filings in 90 days) requires monitoring for potential concerns
- Flat net income despite revenue growth suggests cost pressures or one-time noise
- Relatively low gross margin (25%) leaves less buffer for pricing/mix headwinds
- Operational execution risk to sustain growth and expand margins
Key Metrics to Watch
- Gross and operating margin trends—ability to expand margins with scale will determine earnings power
- Operating cash flow sustainability and free cash flow conversion ratio
- Revenue growth trajectory by segment and geographic region to assess durability
- Capital allocation decisions (M&A, R&D investment, shareholder returns) indicating management confidence
- Gross margin trend
- Operating margin and expense leverage
Globus Medical Inc. (GMED) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 20.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 4.26x current ratio provides a solid financial cushion.
GMED Profit Margin, ROE & Profitability Analysis
GMED vs Healthcare Sector: How Globus Medical Inc. Compares
How Globus Medical Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Globus Medical Inc. Stock Overvalued? GMED Valuation Analysis 2026
Based on fundamental analysis, Globus Medical Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Globus Medical Inc. Balance Sheet: GMED Debt, Cash & Liquidity
GMED Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Globus Medical Inc.'s revenue has grown significantly by 207% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.07 reflects profitable operations.
GMED Revenue Growth, EPS Growth & YoY Performance
GMED Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $625.7M | $51.8M | $0.38 |
| Q2 2025 | $629.7M | $24.6M | $0.18 |
| Q1 2025 | $598.1M | -$7.1M | $-0.05 |
| Q3 2024 | $383.6M | $998.0K | $0.01 |
| Q2 2024 | $291.6M | $24.6M | $0.18 |
| Q1 2024 | $276.7M | -$7.1M | $-0.05 |
| Q3 2023 | $254.1M | $998.0K | $0.01 |
| Q2 2023 | $263.6M | $54.6M | $0.53 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Globus Medical Inc. Dividends, Buybacks & Capital Allocation
GMED SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Globus Medical Inc. (CIK: 0001237831)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GMED
What is the AI rating for GMED?
Globus Medical Inc. (GMED) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GMED's key strengths?
Claude: Outstanding free cash flow generation at 20% of revenue with minimal capex burden. Fortress balance sheet: zero debt, $526.2M cash position, 4.26x current ratio for substantial financial flexibility. ChatGPT: Debt-free balance sheet with strong liquidity (current ratio 4.26x, cash ~$526M). Robust cash generation (OCF > NI, ~20% FCF margin).
What are the risks of investing in GMED?
Claude: Net income grew 0% YoY despite 16.7% revenue growth, suggesting either margin compression or non-recurring items that warrant investigation. Medical device sector faces regulatory headwinds, competitive pricing pressure, and dependency on discretionary surgical procedures. ChatGPT: Flat net income despite revenue growth suggests cost pressures or one-time noise. Relatively low gross margin (25%) leaves less buffer for pricing/mix headwinds.
What is GMED's revenue and growth?
Globus Medical Inc. reported revenue of $2.9B.
Does GMED pay dividends?
Globus Medical Inc. does not currently pay dividends.
Where can I find GMED SEC filings?
Official SEC filings for Globus Medical Inc. (CIK: 0001237831) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GMED's EPS?
Globus Medical Inc. has a diluted EPS of $3.92.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GMED a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Globus Medical Inc. has a BUY rating with 78% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is GMED stock overvalued or undervalued?
Valuation metrics for GMED: ROE of 11.8% (sector avg: 15%), net margin of 18.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GMED stock in 2026?
Our dual AI analysis gives Globus Medical Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is GMED's free cash flow?
Globus Medical Inc.'s operating cash flow is $753.4M, with capital expenditures of $164.7M. FCF margin is 20.0%.
How does GMED compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 18.3% (avg: 12%), ROE 11.8% (avg: 15%), current ratio 4.26 (avg: 2).